The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Response to immunotherapy, platinum-based chemotherapy or their combination in metastatic urothelial carcinoma (MUC) with or without FGFR-3 alterations: Single cohort experience.
 
Laura Ferrer-Mileo
No Relationships to Disclose
 
Adela Rodriguez
No Relationships to Disclose
 
Nuria González
No Relationships to Disclose
 
Mayra Orrillo
No Relationships to Disclose
 
Natalia Jiménez
No Relationships to Disclose
 
Mercedes Marín-Aguilera
No Relationships to Disclose
 
Leonardo Rodriguez-Carunchio
No Relationships to Disclose
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; NanoString Technologies (Inst); Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics
 
Begona Mellado
No Relationships to Disclose
 
Oscar Reig
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Sanofi
Travel, Accommodations, Expenses - Ipsen